Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Progression‐free survival · people with cutaneous melanoma

BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.27 [0.21, 0.34]
925 participants
High

Progression‐free survival · people with cutaneous melanoma

BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.56 [0.44, 0.71]
1784 participants
Moderate